专利检索 ap:"Christopher R MOYES" 第 1 页

1.

发明授权
Pyrrolidine derived beta 3 adrenergic receptor agonists 有权
标题翻译：吡咯烷衍生的β3肾上腺素能受体激动剂

公开(公告)号：US08354403B2

公开(公告)日：2013-01-15

申请号：US13392662

申请日：2010-08-17

申请人： Scott D. Edmondson , Richard Berger , Lehua Chang , Vincent J. Colandrea , Jeffrey J. Hale , Bart Harper , Nam Fung Kar , Bing Li , Greg J. Morriello , Christopher R. Moyes , Deyou Sha , Dong-Ming Shen , Liping Wang , Harvey Wendt , Cheng Zhu

发明人： Scott D. Edmondson , Richard Berger , Lehua Chang , Vincent J. Colandrea , Jeffrey J. Hale , Bart Harper , Nam Fung Kar , Bing Li , Greg J. Morriello , Christopher R. Moyes , Deyou Sha , Dong-Ming Shen , Liping Wang , Harvey Wendt , Cheng Zhu

IPC分类号： A61K31/536 , A61K31/438 , A61K31/4245 , C07D265/12 , C07D221/20 , C07D413/14

CPC分类号： C07D403/14 , C07D401/04 , C07D401/10 , C07D401/14 , C07D403/10 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/10 , C07D491/048 , C07D491/107 , C07D491/147 , C07D491/20 , C07D495/10 , C07D495/20 , C07D497/10 , C07D498/04 , C07D513/04 , C07D513/20

摘要： The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

摘要翻译： 本发明提供式（I）化合物，其药物组合物及其用于治疗或预防由β-肾上腺素能受体激活介导的疾病的方法。

2.

发明申请
GLUCOSE-RESPONSIVE INSULIN CONJUGATES 有权

公开(公告)号：US20220273770A1

公开(公告)日：2022-09-01

申请号：US17629501

申请日：2020-07-23

申请人： Danqing FENG , Erin N. GUIDRY , Pei HUO , Andrew J. KASSICK , Ahmet KEKEC , Songnian LIN , Christopher R MOYES , Dmitri A. PISSARNITSKI , Lin YAN , Yuping ZHU , Merck Sharp & Dohme Corp.

发明人： Danqing Feng , Erin N. Guidry , Pei Huo , Andrew J. Kassick , Ahmet Kekec , Songnian Lin , Christopher R. Moyes , Dmitri A. Pissarnitski , Lin Yan , Yuping Zhu

IPC分类号： A61K38/28 , A61K47/54 , A61P3/10

摘要： Glucose-responsive insulin conjugates that contain one or more trisaccharides are provided. Such insulin conjugates may display a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose, even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule.

3.

发明申请
NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS 有权

公开(公告)号：US20120157432A1

公开(公告)日：2012-06-21

申请号：US13392662

申请日：2010-08-17

申请人： Scott D. Edmondson , Richard Berger , Lehua Chang , Vincent j. Colandrea , Jeffrey J. Hale , Bart Harper , Nam Fung Kar , Bing Li , Greg J. Morriello , Christopher R. Moyes , Deyou Sha , Dong-Ming Shen , Liping Wang , Harvey Wendt , Cheng Zhu

发明人： Scott D. Edmondson , Richard Berger , Lehua Chang , Vincent j. Colandrea , Jeffrey J. Hale , Bart Harper , Nam Fung Kar , Bing Li , Greg J. Morriello , Christopher R. Moyes , Deyou Sha , Dong-Ming Shen , Liping Wang , Harvey Wendt , Cheng Zhu

IPC分类号： A61K31/4025 , A61K31/4155 , C07D403/12 , A61K31/497 , C07D413/14 , A61K31/4245 , C07D209/96 , A61K31/407 , C07D401/14 , A61K31/4439 , C07D487/04 , A61K31/519 , C07D401/12 , A61K31/454 , C07D221/20 , A61K31/438 , A61K31/4545 , C07D265/12 , A61K31/536 , A61K31/501 , A61K31/496 , A61P13/02 , C07D403/14

CPC分类号： C07D403/14 , C07D401/04 , C07D401/10 , C07D401/14 , C07D403/10 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/10 , C07D491/048 , C07D491/107 , C07D491/147 , C07D491/20 , C07D495/10 , C07D495/20 , C07D497/10 , C07D498/04 , C07D513/04 , C07D513/20

摘要： The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

4.

发明申请
HETEROCYCLYL-SUBSTITUTED ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS 审中-公开
标题翻译：杂环取代的抗高血压化合物

公开(公告)号：US20100069347A1

公开(公告)日：2010-03-18

申请号：US12513010

申请日：2007-10-30

申请人： Gregori J. Morriello , Robert J. DeVita , Christopher R. Moyes

发明人： Gregori J. Morriello , Robert J. DeVita , Christopher R. Moyes

IPC分类号： A61K31/397 , C07D205/08 , A61P9/10

CPC分类号： C07D403/10 , C07D413/12 , C07D417/10

摘要： This invention provides cholesterol absorption inhibitors of Formula I: and the pharmaceutically acceptable salts thereof, wherein R12 is a hydroxylated alkyl group and R9 contains a heterocyclic ring. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating atherosclerosis and preventing atherosclerotic disease events.

摘要翻译： 本发明提供式I的胆固醇吸收抑制剂及其药学上可接受的盐，其中R12是羟基化烷基，R9包含杂环。该化合物可用于降低血浆胆固醇水平，特别是低密度脂蛋白胆固醇，以及治疗动脉粥样硬化和预防动脉粥样硬化疾病事件。

5.

发明授权
Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity 失效
标题翻译：杂环环四氢异喹啉和四氢吡啶并吡啶调节剂的趋化因子受体活性

公开(公告)号：US07598243B2

公开(公告)日：2009-10-06

申请号：US10260008

申请日：2004-10-15

申请人： Gabor Butora , Stephen D. Goble , Alexander Pasternak , Lihu Yang , Changyou Zhou , Christopher R. Moyes

发明人： Gabor Butora , Stephen D. Goble , Alexander Pasternak , Lihu Yang , Changyou Zhou , Christopher R. Moyes

IPC分类号： A61K31/5377 , C07D413/08 , C07D413/14

CPC分类号： C07D401/08 , C07D217/06 , C07D401/12 , C07D401/14 , C07D413/08 , C07D471/04 , C07D491/08 , C07D519/00

摘要： The present invention is directed to compounds of the formula I: Wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X, n and the broken lines are as defined herein which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.

摘要翻译： 本发明涉及式I化合物：其中R1，R2，R3，R4，R5，R6，R7，R8，R9，X，n和虚线如本文所定义，其可用作趋化因子受体的调节剂活动。特别地，这些化合物可用作趋化因子受体CCR-2的调节剂。

6.

发明申请
Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity 失效
标题翻译：杂环环四氢异喹啉和四氢吡啶并吡啶调节剂的趋化因子受体活性

公开(公告)号：US20080081803A1

公开(公告)日：2008-04-03

申请号：US10260008

申请日：2004-10-15

申请人： Gabor Butora , Stephen D. Goble , Alexander Pastemak , Lihu Yang , Changyou Zhou , Christopher R. Moyes

发明人： Gabor Butora , Stephen D. Goble , Alexander Pastemak , Lihu Yang , Changyou Zhou , Christopher R. Moyes

IPC分类号： A61K31/4725 , A61K31/4709 , A61K31/496 , A61K31/4985 , A61K31/506 , A61K31/5377 , A61K31/55 , A61K31/551 , A61K31/553 , A61P19/02 , A61P29/00 , A61P35/00 , A61P37/00 , C07D401/08 , C07D401/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D491/08

CPC分类号： C07D401/08 , C07D217/06 , C07D401/12 , C07D401/14 , C07D413/08 , C07D471/04 , C07D491/08 , C07D519/00

摘要： The present invention is directed to compounds of the formula I: Wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X, n and the broken lines are as defined herein which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.

摘要翻译： 本发明涉及式I化合物：其中R 1，R 2，R 3，R 4， R 5，R 6，R 7，R 8，R 9， SUB，X，n，虚线如本文所定义，其可用作趋化因子受体活性的调节剂。特别地，这些化合物可用作趋化因子受体CCR-2的调节剂。

7.

发明申请
GLUCOSE-RESPONSIVE INSULIN CONJUGATES 有权
标题翻译：葡萄糖反应性胰岛素结合

公开(公告)号：US20160251407A1

公开(公告)日：2016-09-01

申请号：US15025912

申请日：2014-10-02

申请人： Songnian LIN , Lin YAN , Ahmet KEKEC , Yuping ZHU , David N. HUNTER , Pei HUO , Danqing FENG , Ravi P. NARGUND , Christopher R. MOYES , Zhiqiang ZHAO , Brenda PIPIK , Dimitri PISSARNITSKI , Joseph L. DUFFY , Erin N. GUIDRY , MERCK SHARP & DOHME CORP.

发明人： Songnian Lin , Lin Yan , Ahmet Kekec , Yuping Zhu , David N. Hunter , Pei Huo , Danqing Feng , Ravi P. Nargund , Christopher R. Moyes , Zhiqiang Zhao , Brenda Pipik , Dmitri Pissarnitski , Joseph L. Duffy , Erin Guidry

IPC分类号： C07K14/62 , A61K38/28 , A61K47/48

CPC分类号： A61K47/61 , A61K38/28 , A61K47/549 , A61K47/64 , C07K14/62

摘要： Insulin conjugates comprising an insulin molecule covalently attached to at least one bi-dentate linker having two arms, each arm independently attached to a ligand comprising a saccharide and wherein at least one ligand of the linker is fucose are disclosed. The insulin conjugates display a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.

摘要翻译： 胰岛素缀合物包含共价连接到具有两个臂的至少一个双齿连接体的胰岛素分子，每个臂独立地连接到包含糖的配体，并且其中至少一个连接体的配体是岩藻糖。胰岛素缀合物显示药代动力学（PK）和/或药效学（PD）谱，其对糖类如葡萄糖或α-甲基甘露糖的全身浓度有反应，即使在不存在外源多价的情况下施用于有需要的受试者时糖结合分子如Con A.

8.

发明申请
A Method of Treating Cancer 审中-公开
标题翻译：一种治疗癌症的方法

公开(公告)号：US20090012061A1

公开(公告)日：2009-01-08

申请号：US11662396

申请日：2005-09-09

申请人： Timothy A. Blizzard , Carolyn A. Buser-Doepner , Douglas E. Frantz , Kelly Hamilton , Myle Hoang , Ling Lee , Christopher R. Moyes , Jerry A. Murry , Arash Soheili

发明人： Timothy A. Blizzard , Carolyn A. Buser-Doepner , Douglas E. Frantz , Kelly Hamilton , Myle Hoang , Ling Lee , Christopher R. Moyes , Jerry A. Murry , Arash Soheili

IPC分类号： G01N33/574 , C12N9/99 , A61K31/403 , A61K31/428 , C07C271/06 , A61K31/27 , A61K31/47 , C07D215/38 , C07C39/12 , A61K31/05 , C07C275/28 , A61K31/17 , A61K31/165 , A61K31/415 , A61K31/44 , A61K31/5415 , A61K31/551 , A61P35/00

CPC分类号： C12Q1/42 , G01N33/6893 , G01N2500/00

摘要： The present invention relates to a method of treating cellular proliferative diseases, in particular cancer, which comprises administering a modulator of the activity of the mitotic kinesin KSP, wherein the activity of the KSP modulator is dependent on the presence of microtubules. It is believed that the KSP modulators utilized in the instant method bind to the KSP protein in a previously unreported manner, since the compounds do not bind competitively with respect to either microtubules or ATP, the substrates of KSP. The modulators useful in the instant methods are furthermore not active against the non-microtubule stimulated activity of KSP. Cellular proliferative diseases that may be treated using the method disclosed herein are, for example cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders and inflammation.

摘要翻译： 本发明涉及一种治疗细胞增殖性疾病，特别是癌症的方法，其包括施用有丝分裂驱动蛋白KSP活性的调节剂，其中KSP调节剂的活性取决于微管的存在。相信本方法中使用的KSP调节剂以先前未报道的方式结合KSP蛋白质，因为化合物相对于微管或ATP（KSP的底物）竞争性结合。在本方法中有用的调节剂还不能抵抗KSP的非微管刺激活性。可以使用本文公开的方法治疗的细胞增殖性疾病是例如癌症，增生，再狭窄，心脏肥大，免疫疾病和炎症。